Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2020 16:05 ET | Source: Annovis Bio Inc.

Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
December 03, 2020 09:15 ET | Source: Annovis Bio Inc.

Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference

BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
November 16, 2020 09:15 ET | Source: Annovis Bio Inc.

Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium

BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
November 12, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
November 02, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio CEO to Present at Meridian Clinical Trials Summit

BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
October 29, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay

BERWYN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
October 22, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award

BERWYN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
October 20, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair

BERWYN, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
October 15, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights

BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
October 12, 2020 16:05 ET | Source: Annovis Bio Inc.

Annovis Bio to Present at the 2020 BIO Investor Forum

BERWYN, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right